845 related articles for article (PubMed ID: 24905005)
1. Cancer epigenetics: tumor heterogeneity, plasticity of stem-like states, and drug resistance.
Easwaran H; Tsai HC; Baylin SB
Mol Cell; 2014 Jun; 54(5):716-27. PubMed ID: 24905005
[TBL] [Abstract][Full Text] [Related]
2. Epigenetics and metabolism at the crossroads of stress-induced plasticity, stemness and therapeutic resistance in cancer.
Ravindran Menon D; Hammerlindl H; Torrano J; Schaider H; Fujita M
Theranostics; 2020; 10(14):6261-6277. PubMed ID: 32483452
[TBL] [Abstract][Full Text] [Related]
3. Stem cell programs in cancer initiation, progression, and therapy resistance.
Huang T; Song X; Xu D; Tiek D; Goenka A; Wu B; Sastry N; Hu B; Cheng SY
Theranostics; 2020; 10(19):8721-8743. PubMed ID: 32754274
[TBL] [Abstract][Full Text] [Related]
4. Perturbation-Driven Entropy as a Source of Cancer Cell Heterogeneity.
Nijman SMB
Trends Cancer; 2020 Jun; 6(6):454-461. PubMed ID: 32460001
[TBL] [Abstract][Full Text] [Related]
5. Addressing intra-tumoral heterogeneity and therapy resistance.
Rybinski B; Yun K
Oncotarget; 2016 Nov; 7(44):72322-72342. PubMed ID: 27608848
[TBL] [Abstract][Full Text] [Related]
6. Emerging Mechanisms by which EMT Programs Control Stemness.
Wilson MM; Weinberg RA; Lees JA; Guen VJ
Trends Cancer; 2020 Sep; 6(9):775-780. PubMed ID: 32312682
[TBL] [Abstract][Full Text] [Related]
7. Noncoding RNAs in Cancer Cell Plasticity.
Xu J; Liu S
Adv Exp Med Biol; 2016; 927():173-89. PubMed ID: 27376735
[TBL] [Abstract][Full Text] [Related]
8. Intratumoral Heterogeneity: From Diversity Comes Resistance.
Pribluda A; de la Cruz CC; Jackson EL
Clin Cancer Res; 2015 Jul; 21(13):2916-23. PubMed ID: 25838394
[TBL] [Abstract][Full Text] [Related]
9. Drug resistance, epigenetics, and tumor cell heterogeneity.
Hoey T
Sci Transl Med; 2010 Apr; 2(28):28ps19. PubMed ID: 20410528
[TBL] [Abstract][Full Text] [Related]
10. Loss of insulin-like growth factor II imprinting is a hallmark associated with enhanced chemo/radiotherapy resistance in cancer stem cells.
Zhao X; Liu X; Wang G; Wen X; Zhang X; Hoffman AR; Li W; Hu JF; Cui J
Oncotarget; 2016 Aug; 7(32):51349-51364. PubMed ID: 27275535
[TBL] [Abstract][Full Text] [Related]
11. Mathematical models of cell phenotype regulation and reprogramming: Make cancer cells sensitive again!
Wooten DJ; Quaranta V
Biochim Biophys Acta Rev Cancer; 2017 Apr; 1867(2):167-175. PubMed ID: 28396217
[TBL] [Abstract][Full Text] [Related]
12. Cancer stem cells: understanding tumor hierarchy and heterogeneity.
Rich JN
Medicine (Baltimore); 2016 Sep; 95(1 Suppl 1):S2-S7. PubMed ID: 27611934
[TBL] [Abstract][Full Text] [Related]
13. Epigenetics as a mediator of plasticity in cancer.
Feinberg AP; Levchenko A
Science; 2023 Feb; 379(6632):eaaw3835. PubMed ID: 36758093
[TBL] [Abstract][Full Text] [Related]
14. Epigenetic mechanisms in tumorigenesis, tumor cell heterogeneity and drug resistance.
Wilting RH; Dannenberg JH
Drug Resist Updat; 2012; 15(1-2):21-38. PubMed ID: 22356866
[TBL] [Abstract][Full Text] [Related]
15. Epigenetic regulation of cancer stem cells: Shedding light on the refractory/relapsed cancers.
Xu L; Zhang J; Sun J; Hou K; Yang C; Guo Y; Liu X; Kalvakolanu DV; Zhang L; Guo B
Biochem Pharmacol; 2022 Aug; 202():115110. PubMed ID: 35640714
[TBL] [Abstract][Full Text] [Related]
16. Activation of Matrix Hyaluronan-Mediated CD44 Signaling, Epigenetic Regulation and Chemoresistance in Head and Neck Cancer Stem Cells.
Bourguignon LYW; Earle C; Shiina M
Int J Mol Sci; 2017 Aug; 18(9):. PubMed ID: 28837080
[TBL] [Abstract][Full Text] [Related]
17. Basal/HER2 breast carcinomas: integrating molecular taxonomy with cancer stem cell dynamics to predict primary resistance to trastuzumab (Herceptin).
Martin-Castillo B; Oliveras-Ferraros C; Vazquez-Martin A; Cufí S; Moreno JM; Corominas-Faja B; Urruticoechea A; Martín ÁG; López-Bonet E; Menendez JA
Cell Cycle; 2013 Jan; 12(2):225-45. PubMed ID: 23255137
[TBL] [Abstract][Full Text] [Related]
18. Long Noncoding RNA
Chen X; Xie R; Gu P; Huang M; Han J; Dong W; Xie W; Wang B; He W; Zhong G; Chen Z; Huang J; Lin T
Clin Cancer Res; 2019 Feb; 25(4):1389-1403. PubMed ID: 30397178
[TBL] [Abstract][Full Text] [Related]
19. Reprogramming cancer cells: a novel approach for cancer therapy or a tool for disease-modeling?
Yilmazer A; de Lázaro I; Taheri H
Cancer Lett; 2015 Dec; 369(1):1-8. PubMed ID: 26276716
[TBL] [Abstract][Full Text] [Related]
20. Long non-coding RNAs in cancer drug resistance development.
Majidinia M; Yousefi B
DNA Repair (Amst); 2016 Sep; 45():25-33. PubMed ID: 27427176
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
